Most recently it has been demonstrated that the higher the proportion of tumour infiltrating lymphocytes on core biopsy of breast cancer, the greater the likelihood of a pathological complete remission following neoadjuvant chemotherapy and Herceptin, in Her2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.